Archive- English:


You will hear from leading myeloma experts from the International Myeloma Working Group, including:

Dr. Brian G.M. Durie, International Myeloma Foundation
Dr. Paul G. Richardson, Dana Farber Cancer Institute, U.S.
Dr. Xavier Leleu, Hopital Claude Huriez, France
Dr. Robert Orlowski, The University of Texas MD Anderson Cancer Center, U.S.

Patients will also speak about the latest treatments from their personal perspectives.
Antonio Palumbo, M.D.

Dr. Antonio Palumbo received his medical degree from the University of Torino, Italy, where he served his residency in internal medicine and held a fellowship in hematology/oncology. Before his current position as chief of the Myeloma Unit of the Department of Oncology, Section of Hematology at the University of Torino, Dr. Palumbo was a research associate at the Wistar Institute, University of Pennsylvania.

In addition to being a member of numerous professional organizations, including the Italian Society of Hematology, Italian Society of Experimental Hematology, European Society of Hematology, American Society of Hematology, and the American Society of Clinical Oncology, Dr. Palumbo is on the Board of Directors of the International Myeloma Society. He has authored more than 150 publications in peer-reviewed journals as well numerous abstracts and several textbooks chapters. Dr. Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia. His current research focuses on the pathogenesis and treatment of multiple myeloma.

Brian G. M. Durie, M.D.

Dr. Brian Durie is an attending physician at the Cedars-Sinai Medical Center with clinical expertise is in multiple myeloma. He is the senior advisor for Hematologic Malignancies, national program director for Multiple Myeloma and Related Disorders for Aptium Oncology, and along with Dr. Sydney Salmon, co-created the Durie/Salmon Staging System, which is used worldwide for evaluating patients with myeloma.

Previously, Dr. Durie was a professor at the University of Arizona College of Medicine and the Charing Cross and Westminster School of Medicine at the University of London. He is board-certified by the American Board of Internal Medicine with subspecialties in both medical oncology and hematology.

Dr. Durie is the recipient of numerous honors and awards for excellence, which include the Leukemia Society of America Scholar U.S. Hematologic Research Foundation and 2006 Robert A. Kyle Lifetime Achievement awards. He has written over 400 research papers, 16 book chapters and five books; he has published research manuscripts in both basic research journals as well as major clinical journals such as the New England Journal of Medicine. He is also an international patent holder for scintillation autoradiography.

Additionally, Dr. Durie founded and now chairs the International Myeloma Foundation, serving on its Scientific Advisory Board. Dr. Durie is also a Marquis member of "Who's Who in America" publication and "The Best Doctors in America" online resource.

Dr. Durie completed his residencies and fellowships at the Mayo Clinic and the University of Minnesota. He received his medical degree from the University of Edinburgh Medical School, Scotland in 1966.

Paul Richardson, M.D.

Dr. Paul Richardson is an associate professor of medicine at Harvard Medical School, clinical director at the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute and a lecturer both nationally and internationally. He is board-certified in internal medicine, medical oncology and hematology. Dr. Richardson is currently leading multiple efforts studying the use of combination therapies in relapsed and refractory myeloma.

Additionally, Dr. Richardson holds leadership positions in several professional bodies and serves on the editorial board of the Journal of Clinical Oncology, Journal of Oncology, American Journal of Hematology/Oncology, The Oncologist and Clinical Cancer Research. He also previously served as chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core from 2004 to 2009.

Dr. Richardson has published more than 200 original articles, and more than 100 reviews, chapters and editorials in top peer-reviewed journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, Clinical Cancer Research and British Journal of Hematology.

His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Women’s Hospital Teaching Scholars Award; the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care; and the Tisch Family Outstanding Achievement Award in Translational Research. Most recently, he was awarded a Fellowship of the Royal College of Physicians (UK) in recognition of his contributions in hematologic oncology and, in particular, multiple myeloma.

Dr. Richardson earned his medical degree at Medical College of St. Bartholomew's Hospital in London, UK and completed a fellowship at Baystate Medical Center of Tufts University School of Medicine in the U.S.

Robert Orlowski, M.D.

Dr. Robert Z. Orlowski is Associate Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy, with a focus on the molecular pathogenesis of oncologic disease processes and the mechanisms of action of chemotherapeutics.

Susie Novis

Susie Novis founded the International Myeloma Foundation (IMF) in 1990, along with her late husband Brian Novis and hematologist/multiple myeloma specialist Dr. Brian Durie. Novis brings to the IMF a background as a business executive along with her personal drive and commitment to myeloma patients based on her own experience.

Shortly after she and Brian were engaged, he was diagnosed with myeloma. Like everyone who hears the words multiple myeloma for the first time, they were in shock and, worst of all, they felt completely alone. At the time, there was no place for myeloma patients and their families to turn for help or support, which is what encouraged them to establish the IMF.

"We wanted to help prevent future myeloma patients and their families from experiencing the same sense of isolation we had to struggle with," said Novis.

Less than four years after his diagnosis, Brian succumbed to the disease; he was 37 years old. Novis was devastated but she and Dr. Durie agreed to continue the work of the Foundation—the work Brian had begun.

In 1992, Novis was elected executive director of the IMF and became its first president, a title she still holds today. Under her direction, the IMF has grown from three people to 195,000 members in 113 countries around the world. The IMF has raised over $50 million, with more than 89 percent going directly to support IMF programs and myeloma research.

Novis started the IMF's flagship Patient & Family Seminars program in 1993 to bring experts and information directly to people affected by myeloma. To date, the IMF has held over 200 of these seminars in 15 countries around the world. Novis has also overseen the development of multi-lingual patient materials; the IMF distributes more than 25,000 information packets each year in more than 13 languages.

To support research, in 2003 she conceived of Bank On A Cure®, the first-ever myeloma specific DNA databank, and she developed the IMF Scientific Advisory Board Retreat to bring the world's myeloma experts together to engage in focused scientific discussions.

Novis has testified before Congress, urging for greater resources for myeloma research, and each year she logs more than 100,000 miles to personally help bring information and inspiration to patients and families in need. Novis is the recipient of the Joseph Michaeli Award and the Baylor-Charles A. Sammons Cancer Center Award for her outstanding contributions to the understanding and treatment of myeloma.

Novis was born and raised in Connecticut. She graduated from Curry College, Milton, Massachusetts and currently resides in Los Angeles.

Xavier Leleu, M.D.

Dr. Xavier Leleu is an associate professor in the Department of Haematology at Hôpital Claude Huriez, part of the academic hospital in Lille, France. Dr. Leleu received his medical degree at the University of Bordeaux, France. He completed specialties in public healthcare and statistics at the University of Medicine of Paris, France and in hematology at the University of Medicine of Lille. Dr. Leleu has trained in myeloma since 1995 with Prof. T. Facon as his mentor in Lille, and became instructor in charge of the myeloma clinic of the academic hospital of Lille in 2002 under the supervision of Prof. T. Facon.

He received a Master’s in cellular biology at the University of Medicine of Lille in 2001 and completed his Ph.D. in 2007 having done his research at Dana-Farber Cancer Institute, affiliated with Harvard Medical School, Boston, U.S. His main topic of research was the preclinical development of the novel agent PI3K/Akt/mTOR signalling pathway in Waldenström macroglobulinemia and multiple myeloma with his mentor Dr. IM Ghobrial in Professor Kenneth Anderson’s laboratory.

Dr. Leleu has also trained in research and clinic in the Waldenström macroglobulinemia field with Dr. S. Treon, a worldwide known expert in macroglobulinemia. Dr. Leleu is on the editorial board of The Hematologist, Hématologie, and Correspondance en Onco-Hématologie, and is a reviewer for several notable journals in the field of hematology including: Blood, British Journal of Haematology, Cancer Research, Clinical Cancer Research, Haematologica, and Leukemia, among many others.

He is also a member of many scientific societies including the American Society of Hematology, the European Hematology Association, Intergroupe Francophone du Myélome, the International Myeloma Working Group, and the International Waldenström’s Macroglobulinemia Foundation. Dr. Leleu has published widely in the field of hematology both in journals and books, and is very active in preclinical and clinical trial research.
The International Myeloma Foundation (IMF), with Myeloma Canada and the IMF Latin America, is sponsoring a Journalists' Workshop Sunday evening at ASH 2012 (American Society of Hematology Annual Meeting) to discuss and analyze the very latest treatments for multiple myeloma, and how advancements will affect patient treatment.

Myeloma is the second most prevalent blood cancer, and although it cannot be cured, new treatment regimens are providing many patients with long-term remissions and a good quality of life.

Share on:

Have a question for us? Please submit below:

Archive - Portuguese

Archive - Russian

Archive - Mandarin